Press Releases
| April 11, 2013 | Theratechnologies Announces Financial Results for First Quarter of 2013 |
| April 9, 2013 | Theratechnologies Board of Directors Appoints Former Merck Canada President |
| April 8, 2013 | Theratechnologies Announces Termination of Agreement With Ferrer |
| April 3, 2013 | Renegotiated Lease to Generate Substantial Annual Savings |
| March 25, 2013 | Health Canada Decision Appealed |
| March 4, 2013 | Health Canada Issues Decision on Tesamorelin |
| February 27, 2013 | Theratechnologies Announces Financial Results for Fiscal Year 2012 |
| February 14, 2013 | Theratechnologies to Announce Financial Results for Fiscal Year 2012 |
| February 5, 2013 | Theratechnologies Announces Completion of NASDAQ Delisting |
| January 29, 2013 | Theratechnologies Secures US Patent for its Novel Peptide TH1173 |
| January 21, 2013 | FDA approves alternative storage conditions for EGRIFTA(TM) |
| January 14, 2013 | Theratechnologies Announces Intent to Voluntarily Delist from NASDAQ |
| October 30, 2012 | Revenue Growth and Expenditure Control at the Core of Revised Business Plan |
| October 29, 2012 | Theratechnologies to Host Conference Call |
| October 11, 2012 | Theratechnologies Announces Financial Results for Third Quarter of 2012 |
| October 11, 2012 | Theratechnologies Announces Departure of President and Chief Executive Officer |
| October 10, 2012 | Theratechnologies Provides Follow-Up Regulatory Update on Tesamorelin |
| October 3, 2012 | Theratechnologies to Announce Financial Results for Third Quarter Of 2012 |
| August 7, 2012 | Theratechnologies Receives Notification from NASDAQ Relating to Minimum Bid Priceum Bid Price |
| July 12, 2012 | Theratechnologies Announces Financial Results for Second Quarter of 2012 |
| July 9, 2012 | Theratechnologies to announce financial results for second quarter of 2012 |
| June 27, 2012 | New Phase II, NIH-sponsored study demonstrates metabolic effects of tesamorelin in obese subjects with reduced growth hormone secretion |
| June 22, 2012 | Theratechnologies Provides Regulatory Update on Tesamorelin |
| June 4, 2012 | Tesamorelin Filed for Marketing Approval in Colombia and Venezuela |
| May 15, 2012 | Reminder: Theratechnologies Annual Meeting of Shareholders |
| May 10, 2012 | New GRF Peptide TH1173 Enters Important Pre-Clinical Phase |
| May 2, 2012 | Theratechnologies Annual Meeting of Shareholders: Location Change |
| April 13, 2012 | Theratechnologies Announces Financial Results for First Quarter of 2012 |
| March 28, 2012 | Media Advisory: Theratechnologies to Present at Needham Annual Healthcare Conference |
| February 24, 2012 | Theratechnologies: update on motion for authorization to institute class action against the Company |
| February 23, 2012 | Media Advisory: Theratechnologies to Present at RBC Capital Markets Conference |
| February 21, 2012 | Theratechnologies Announces a Supply, Distribution and Licensing Agreement With Actelion Pharmaceuticals Canada |
| February 8, 2012 | Theratechnologies Announces Results for Fiscal Year 2011 |
| January 26, 2012 | Theratechnologies to Announce Results for Its 2011 Fiscal Year |
| December 7, 2011 | Theratechnologies to discontinue COPD clinical program and accelerate path to profitability |
| November 24, 2011 | Theratechnologies Wins ADRIQ’s 2011 Product Innovation Award |
| October 19, 2011 | Theratechnologies Announces Application for Registration of Tesamorelin in Mexico |
| October 13, 2011 | Theratechnologies Announces Financial Results for the Third Quarter of 2011: U.S. Sales of EGRIFTA® Driving Revenue Growth |
| October 6, 2011 | Theratechnologies Identifies Second Generation GRF Peptide and Initiates Pre- Clinical Studies |
| September 6, 2011 | Theratechnologies Launches Phase 2 Clinical Trial to Investigate Tesamorelin for the Treatment of COPD-Associated Muscle Wasting |
| September 1, 2011 | Tesamorelin filed for Marketing Authorization in Argentina |
| August 31, 2011 | Tesamorelin filed for Marketing Authorization in Brazil |
| August 16, 2011 | Health Canada Accepts to Review Theratechnologies’ New Drug Submission for EGRIFTA® |
| July 19, 2011 | Results of Independent Study on the Effect of Tesamorelin on Cognitive Function Presented at Conference in France |
| July 15, 2011 | Theratechnologies: Data Unveiled on the Effect of Tesamorelin on Metabolic Risk Factors at Conference in Italy |
| July 7, 2011 | Theratechnologies Announces Financial Results for the Second Quarter of 2011 |
| July 5, 2011 | Theratechnologies Announces the Filing of an Application for Registration of Tesamorelin in Israel by Sanofi |
| June 27, 2011 | Tesamorelin Accepted for Review by European Medicines Agency |
| June 20, 2011 | Theratechnologies files New Drug Submission for EGRIFTA® with Health Canada |
| June 16, 2011 | Theratechnologies Rings NASDAQ Opening Bell |
| June 13, 2011 | Theratechnologies Announces NASDAQ Listing |
| June 6, 2011 | Theratechnologies Announces Filing of European Marketing Authorization Application for Tesamorelin |
| June 2, 2011 | Theratechnologies Adopts New R&D Business Model to Strengthen its Growth Potential |
| May 18, 2011 | Theratechnologies Holds Annual and Special Meeting of Shareholders After a Year Marked by Historic Achievement |
| May 16, 2011 | Theratechnologies holds annual and special meeting of shareholders |
| April 12, 2011 | Theratechnologies announces results for the first quarter 2011 |
| March 8, 2011 | Theratechnologies decides to withdraw its cross-border offering |
| February 22, 2011 | Theratechnologies files preliminary prospectus for cross-border offering |
| February 22, 2011 | Theratechnologies announces new clinical program in muscle wasting in Chronic Obstructive Pulmonary Disease (COPD) |
| February 9, 2011 | Theratechnologies announces results for the 2010 fiscal year |
| February 3, 2011 | Theratechnologies and Ferrer Announce a Distribution & Licensing Agreement for Tesamorelin in Europe |
| December 6, 2010 | Theratechnologies announces a distribution and licensing agreement for EGRIFTATM in Latin America, Africa and the Middle East with sanofi-aventis |
| December 2, 2010 | Theratechnologies plans early adoption of International Financial Reporting Standards |
| December 1, 2010 | Theratechnologies welcomes the arrival of its new President and CEO |
| November 11, 2010 | FDA Approves EGRIFTATM (tesamorelin for injection): The First and Only Treatment for the Reduction of Excess Abdominal Fat in HIV-Infected Patients with Lipodystrophy |
| October 14, 2010 | Theratechnologies announces the retirement date for the President and CEO: Mr. Yves Rosconi |
| October 12, 2010 | Theratechnologies announces results for the third quarter 2010 Lower burn rate and solid financial position |
| September 13, 2010 | Theratechnologies: tesamorelin data presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy 50th annual meeting |
| September 1, 2010 | Theratechnologies is pleased to announce the appointment of a new president and CEO |
| July 26, 2010 | Theratechnologies receives a motion of authorization to institute a class action |
| July 20, 2010 | Update on timeline for FDA Action Date for Theratechnologies’ tesamorelin New Drug Application |
| July 7, 2010 | Second Quarter 2010: Theratechnologies Reports Lower Burn Rate and Good Financial Position |
| June 29, 2010 | Theratechnologies added to the Russell Global Index |
| June 24, 2010 | Theratechnologies Announces Publication of Combined Tesamorelin Phase 3 Results in JCEM |
| June 2, 2010 | Yves Rosconi, President & CEO of Theratechnologies, will retire on December 31, 2010 |
| May 27, 2010 | Theratechnologies Announces Positive Vote by FDA Advisory Committee for Tesamorelin |
| March 25, 2010 | Theratechnologies Reports Positive Outcome at its Annual and Special Meeting of Shareholders |
| March 23, 2010 | Theratechnologies Announces Financial Results and Closes The First Quarter in a Strong Financial Position |
| March 22, 2010 | FDA Confirms Date for Advisory Committee Review of the Tesamorelin New Drug Application |
| March 1, 2010 | Theratechnologies Announces Publication of Second Phase 3 Results in Jaids |
| February 28, 2010 | Theratechnologies Announces a Tentative New Date for the FDA Advisory Committee Review of the Tesamorelin New Drug Application |
| February 10, 2010 | Milestones Met In 2009 Lead to Optimistic Outlook for Theratechnologies |
| February 10, 2010 | Theratechnologies Adopts Shareholder Rights Plan |
| January 25, 2010 | Theratechnologies Reports that the FDA will Reschedule for Administrative Reasons the Advisory Committee Meeting to Review Tesamorelin’s NDA |
| January 18, 2010 | Theratechnologies Reports Date for FDA Advisory Committee Review of the Tesamorelin New Drug Application |
| December 29, 2009 | Theratechnologies receives patent protection in Brazil for tesamorelin |
| November 11, 2009 | Theratechnologies presents combined Phase 3 clinical results at European AIDS Conference |
| November 5, 2009 | Theratechnologies’ NDA for Tesamorelin to be Reviewed by an FDA Advisory Committee |
| October 26, 2009 | Theratechnologies presents clinically relevant improvements in patient reported outcome parameters |
| October 5, 2009 | Theratechnologies Announces Financial Results for the Third Quarter 2009 |
| August 12, 2009 | Theratechnologies to receive a milestone payment of US $10 million associated with the FDA acceptance to file tesamorelin NDA |
| July 7, 2009 | Theratechnologies Announces Financial Results and Highlights for the Second Quarter 2009 |
| June 19, 2009 | Theratechnologies awarded Le Prix Santé by the Fondation Armand-Frappier |
| June 12, 2009 | Theratechnologies presents results from a pharmacokinetic/phamacodynamic evaluation of tesamorelin at the Endocrine Society’s Annual Meeting |
| June 1, 2009 | Theratechnologies files a New Drug Application for tesamorelin with the US Food and Drug Administration |
| April 27, 2009 | Theratechnologies presents additional data from studies evaluating tesamorelin at the Annual Canadian Conference on HIV/AIDS Research |
| March 26, 2009 | Theratechnologies’ annual and special meeting of shareholders |
| March 25, 2009 | Theratechnologies announces financial results of the first quarter 2009 |
| February 9, 2009 | 2008: A PIVOTAL YEAR FOR THERATECHNOLOGIES |
| February 9, 2009 | Theratechnologies presents data on patients with atherogenic lipid profile from its combined Phase 3 studies at CROI |
| January 9, 2009 | Theratechnologies announces Senior Management Change |
| December 16, 2008 | Theratechnologies Closes its Collaboration and Licensing Transaction with Emd Serono |
| December 15, 2008 | Theratechnologies Announces Expiry of the Waiting Period Under the Hart-Scott Rodino Act |
| December 15, 2008 | Theratechnologies Reports 52-Week Results in its Confirmatory Phase 3 Trial with Tesamorelin |
| November 13, 2008 | Theratechnologies: Last Patient Treated in the Extension Phase of the Confirmatory Study Testing Tesamorelin in HIV-Associated Lipodystrophy |
| November 6, 2008 | Theratechnologies Presents Additional Results from its Tesamorelin Phase 3 Studies at The 10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV |
| October 29, 2008 | Theratechnologies and EMD Serono Announce Collaboration and Licensing Agreement for Tesamorelin in the United States |
| October 9, 2008 | Theratechnologies Announces Financial Results and Highlights For the Third Quarter 2008 |
| September 2, 2008 | Theratechnologies Announces Publication In AIDS |
| August 4, 2008 | Theratechnologies Reports on Positive Body Image Parameters at The International AIDS Conference |
| July 9, 2008 | Theratechnologies Announces Financial Results and Highlights For the Second Quarter 2008 |
| June 20, 2008 | Theratechnologies Comments on Current Market Activity |
| June 18, 2008 | Theratechnologies Reports Positive 26-Week Results for its Second Tesamorelin Phase 3 Trial |
| May 15, 2008 | Theratechnologies Explores Tesamorelin in Growth Hormone Deficient Abdominal Obesity |
| May 12, 2008 | Theratechnologies and PDC Biotech Gmbh Sign License Agreement for Family of Peptides for Preterm Labour and Primary Dysmenorrhea Programs |
| April 17, 2008 | Theratechnologies Receives the 2008 Genesis Innovation Award |
| April 14, 2008 | Theratechnologies: Last Patient Treated in the Confirmatory Study Testing Tesamorelin in HIV-Associated Lipodystrophy |
| March 25, 2008 | Theratechnologies announces financial results and highlights of the first quarter 2008 |
| February 13, 2008 | Theratechnologies Closes $29,750,000 Financing |
| February 6, 2008 | Theratechnologies Presents Additional Results From its Tesamorelin 52-Week Phase 3 Study at the Conference on Retroviruses and Opportunistic Infections |
| February 5, 2008 | Theratechnologies Files Final Base Shelf Prospectus and Prospectus Supplement |
| January 31, 2008 | Theratechnologies Announces Common Share Offering |
| January 29, 2008 | Theratechnologies Announces Review of Strategic Alternatives and Filing of Preliminary Base Shelf Prospectus for up to $35 Million Equity Financing |
| January 23, 2008 | 2007: A Year of Major Accomplishments for Theratechnologies |
| January 8, 2008 | Theratechnologies Extends Patent Protection for Tesamorelin in the Treatment of HIV-Associated Lipodystrophy |
| December 10, 2007 | Theratechnologies Estimates the Market Size for Hivassociated Lipodystrophy is between $811m and $1.3b in 2012 |
| December 5, 2007 | Theratechnologies announces publication of its 26-week Phase 3 data with tesamorelin in the New England Journal of Medicine |
| October 26, 2007 | Theratechnologies Launches Awareness Program in HIV-Associated Lipodystrophy at the European Aids Conference |
| October 10, 2007 | Theratechnologies Reports Third Quarter Results and Recent Corporate Highlights |
| October 9, 2007 | Theratechnologies Announces Acceptance of Late Breaker Abstract at the 11th European AIDS Conference |
| October 1, 2007 | Theratechnologies Reports Positive 52-Week Phase 3 Results for its Lead Drug Candidate Tesamorelin |
| September 26, 2007 | Theratechnologies Announces a License Agreement for its Glucagon-Like Peptide-1 (Glp-1) Portfolio of Compounds |
| September 11, 2007 | Theratechnologies Learns From the FDA That its Tesamorelin Clinical Program is Moving in the Right Direction |
| September 4, 2007 | Theratechnolgoies Completes Patient Recruitment for Tesamorelin in Confirmatory Phase 3 Trial |
| August 9, 2007 | Theratechnologies Appoints Dr. Pierre Caudrelier as Chief Medical Officer |
| August 3, 2007 | Theratechnologies to present at the 27th Annual Canaccord Adams Global Growth Conference in Boston |
| July 18, 2007 | TH9507 Phase 3 clinical update at international HIV meeting: • TH9507 improved the perception of belly image |
| July 17, 2007 | Theratechnologies Regains Japanese Rights for TH9507 |
| July 10, 2007 | Additional Milestones Achieved for Theratechnologies in Second Quarter 2007 |
| June 4, 2007 | TH9507 Phase 3 Clinical Update |
| May 29, 2007 | Theratechnologies Receives the National Biotechnology Award "Company of the Year" |
| May 2, 2007 | Last Patient Treated in First Pivotal TH9507 Study |
| March 29, 2007 | Theratechnologies’ Annual Meeting |
| March 28, 2007 | Theratechnologies Enjoys Strong Momentum in First Quarter 2007 |
| March 1, 2007 | Results from TH9507 Phase 3 Study in HIV-Associated Lipodystrophy Presented at the 14th Conference on Retroviruses and Opportunistic Infections |
| February 27, 2007 | Theratechnologies Closes $57, 750,000 Bought Deal Financing |
| February 21, 2007 | Over-Allotment Option Increases Gross Proceeds Of Financing to $57,750,000 |
| February 19, 2007 | Theratechnologies Files a Final Prospectus |
| February 12, 2007 | Theratechnologies Files Preliminary Prospectus |
| February 8, 2007 | 2006: A year of noteworthy progress for Theratechnologies |
| February 6, 2007 | Theratechnologies Enters Into a Bought Deal Agreement for $52,500,000 |
| December 19, 2006 | Theratechnologies Reports Positive Phase 3 Results for TH9507 in HIV Associated Lipodystrophy |
| October 25, 2006 | Theratechnologies: last patient treated in pivotal TH9507 trial |
| October 12, 2006 | Theratechnologies: Financial results for third quarter of 2006 and recent operating highlights |
| August 23, 2006 | Theratechnologies receives Special Protocol Assessment from FDA for second pivotal Phase 3 trial with TH9507 |
| July 6, 2006 | Independent Data Safety Monitoring Board recommends continuation of Phase 3 trial with TH9507 |
| July 5, 2006 | Theratechnologies: Financial results for second quarter of 2006 and recent operating highlights |
| April 20, 2006 | Theratechnologies raises additional gross proceeds of $1.35 million through exercise of over-allotment option |
| March 30, 2006 | Theratechnologies’ CEO Upbeat on Future Prospects |
| March 29, 2006 | Theratechnologies: First Quarter 2006 Financial Results and Recent Highlights |
| March 28, 2006 | University of Washington to conduct clinical trial with Theratechnologies’ TH9507 - NIH providing US $2.6 million to finance the project |
| March 23, 2006 | Theratechnologies completes patient enrollment for TH9507 in first Phase 3 trial - Results Expected by End of Year |
| March 21, 2006 | Theratechnologies closes $20 475 000 bought deal |
| March 14, 2006 | Theratechnologies files a final prospectus |
| March 8, 2006 | Theratechnologies files preliminary prospectus |
| March 2, 2006 | Theratechnologies enters into a bought deal agreement for $20,475,000 |
| February 8, 2006 | Theratechnologies appoints former Montreal Stock Exchange President and CEO to its Board of Directors |
| February 8, 2006 | Theratechnologies achieves key milestones in 2005 |
| January 13, 2006 | Theratechnologies Notes Passind of Board Membre Andre Delambre |
| January 9, 2006 | Theratechnologies Comments on Stock Activity |